Shandong University of Traditional Chinese Medicine, Shandong, 250002, PR China; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, PR China.
Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200120, PR China.
Free Radic Biol Med. 2023 Jun;202:2-16. doi: 10.1016/j.freeradbiomed.2023.03.016. Epub 2023 Mar 23.
Acute lung injury (ALI) or its severe form, acute respiratory distress syndrome (ARDS) is a life-threatening illness without effective therapeutic interventions currently. Multiple lines of evidence indicated that overwhelming inflammatory responses and impaired epithelial barrier contributed to the pathogenesis of ALI/ARDS. Recently, dopamine (DA) system was identified to participate in various pulmonary diseases. Here, we discovered that dopamine D1-like receptors mainly expressed in macrophages and airway epithelial cells (AECs), which were downregulated by lipopolysaccharide (LPS) challenge in ALI mouse lung. SKF38393 (SKF) is a selective agonist for D1-like receptors and was demonstrated to inhibit excessive inflammatory responses and oxidative stress in THP-1 cell-derived macrophages and Beas-2B cells, as well as improve airway epithelial barrier dysfunction induced by LPS stimulation. Moreover, SKF administration could effectively decrease pulmonary inflammation, ameliorate tissue damage in the LPS-triggered ALI mice. The broad protective actions of SKF might be attributed to the activation of Nrf2 antioxidative system by use of the specific inhibitor, ML385. This study offers evidence of potent immunoregulatory activity of SKF in macrophages, AECs as well as ALI mouse model, which opens novel therapeutic avenues for the intervention of ALI/ARDS.
急性肺损伤 (ALI) 或其严重形式,急性呼吸窘迫综合征 (ARDS),是一种目前尚无有效治疗干预措施的危及生命的疾病。多项证据表明,过度的炎症反应和上皮屏障受损导致了 ALI/ARDS 的发病机制。最近,多巴胺 (DA) 系统被确定参与多种肺部疾病。在这里,我们发现多巴胺 D1 样受体主要在巨噬细胞和气道上皮细胞 (AECs) 中表达,它们在 ALI 小鼠肺中受到脂多糖 (LPS) 挑战的下调。SKF38393 (SKF) 是 D1 样受体的选择性激动剂,已被证明可抑制 THP-1 细胞来源的巨噬细胞和 Beas-2B 细胞中过度的炎症反应和氧化应激,并改善 LPS 刺激诱导的气道上皮屏障功能障碍。此外,SKF 给药可有效减轻 LPS 触发的 ALI 小鼠肺部炎症,改善组织损伤。SKF 的广泛保护作用可能归因于使用特异性抑制剂 ML385 激活 Nrf2 抗氧化系统。这项研究为 SKF 在巨噬细胞、AECs 以及 ALI 小鼠模型中的强大免疫调节活性提供了证据,为 ALI/ARDS 的干预开辟了新的治疗途径。